Literature DB >> 27935817

SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: Emergency management of pituitary apoplexy in adult patients.

Stephanie E Baldeweg1,2, Mark Vanderpump3, Will Drake4, Narendra Reddy5, Andrew Markey6, Gordon T Plant7,2, Michael Powell2, Saurabh Sinha8, John Wass9.   

Abstract

Entities:  

Year:  2016        PMID: 27935817      PMCID: PMC5314810          DOI: 10.1530/EC-16-0057

Source DB:  PubMed          Journal:  Endocr Connect        ISSN: 2049-3614            Impact factor:   3.335


× No keyword cloud information.

Introduction

Classical pituitary apoplexy is a medical emergency and rapid replacement with hydrocortisone may be lifesaving. It is caused by haemorrhage and/or infarction of a tumour within the pituitary gland. A high index of clinical suspicion is essential to diagnose this condition as prompt management may be life and vision saving. This guideline aims to take the non-specialist through the initial phase of assessment and management. The diagnosis of pituitary apoplexy is often delayed as ~80% of these patients will have no previous history of a pituitary problem and the clinical features mimic other more common neurological conditions. A diagnosis of pituitary apoplexy should be considered in all patients who have acute severe headache and any of the following: patients in whom subarachnoid haemorrhage (SAH) and meningitis have been excluded patients with neuro-ophthalmic signs patients with pre-existing pituitary tumours Acute severe headache is the most common and earliest manifestation. Headache may be accompanied by nausea and vomiting Ocular palsies, most commonly a third nerve palsy, can occur due to involvement of the cavernous sinus Reduced visual acuity and visual field defects, most commonly a bi-temporal hemianopia, are due to optic chiasmal compression Fever, neck stiffness, photophobia or reduced consciousness (similar to signs/symptoms of SAH or meningitis) may occur

Precipitating factors

Hypertension, major surgery, especially coronary artery bypass grafting, dynamic testing of the pituitary gland, anticoagulation therapy, coagulopathies, pregnancy and head trauma. SAH due to ruptured intracranial aneurysm or arteriovenous malformation Bacterial/viral meningitis Brainstem infarction Cavernous sinus thrombosis Ensure haemodynamic stability through supportive measures Urgent bloods: urea and electrolytes, full blood count, renal and liver function tests, clotting profile Indications for empirical steroid therapy in patients with pituitary apoplexy are haemodynamic instability, altered consciousness level, reduced visual acuity and severe visual field defects. Steroid replacement is potentially lifesaving in these patients In adults, hydrocortisone 100 mg i.m. bolus followed by 50–100 mg six hourly by intramuscular injection or 100–200 mg as an intravenous bolus followed by 2–4 mg per hour by continuous i.v. infusion can be used Careful assessment of fluid and electrolyte balance Ideally, endocrine evaluation with blood samples for random serum cortisol, TSH, free T4, prolactin, IGF1, LH, FSH, testosterone (men), oestradiol (women) for later analysis Bedside assessment of visual acuity and fields Further neuro-ophthalmic assessments can be undertaken when the patient is clinically stable CT brain (± LP) to exclude SAH and meningitis should be undertaken if not already done Magnetic resonance imaging (MRI) is the investigation of choice and has been shown to confirm the diagnosis in over 90% of patients. A pituitary CT is indicated if MRI is contraindicated or not possible Urgent referral to the joint neurosurgical/endocrine unit for definitive management

After emergency care: where should patients with pituitary apoplexy be managed?

Once the diagnosis has been confirmed, it is recommended that all patients be transferred once medically stabilised, following liaison and advice from the specialist neurosurgical/endocrine team, to the local neurosurgical/endocrine team as soon as possible. Neurosurgical high dependency unit (HDU) facilities must be available. This team must have access to specialist endocrine and ophthalmological expertise. These patients should then be managed according the Society for Endocrinology UK guidelines for the management of pituitary apoplexy (1).

Indications for surgery

Patients should first be stabilised medically with steroid replacement, if needed, before surgical intervention. Studies have shown significantly greater improvement in visual acuity and visual field defects in patients who had early surgery (within 8 days). Surgical intervention should be considered in patients with: Severely reduced visual acuity Severe and persistent visual field defects Deteriorating level of consciousness

Long-term follow-up

All patients with pituitary apoplexy need follow-up by endocrine and neurosurgical teams. They require repeat assessment of pituitary and visual function, at 4–6 weeks. Thereafter, 6–12 monthly follow-up to optimise hormonal replacement and to monitor tumour progression/recurrence.

Summary

See Fig. 1 for an emergency management summary.
Figure 1

Pituitary apoplexy emergency management summary.

Pituitary apoplexy emergency management summary. Pituitary apoplexy is a rare and potentially lethal endocrine emergency, characterised by acute severe headache, visual defects, and/or reduced consciousness. The clinical presentation often mimics other more common neurological emergencies. Prompt resuscitation and corticosteroid replacement may be lifesaving. MRI scan is the investigation of choice. Urgent discussion with the regional neurosurgical/endocrine team is essential. Surgical intervention should be considered in patients with severe and persisting visual defects or in those with deteriorating level of consciousness after medical stabilisation and steroid replacement.
  1 in total

1.  UK guidelines for the management of pituitary apoplexy.

Authors:  Senthil Rajasekaran; Mark Vanderpump; Stephanie Baldeweg; Will Drake; Narendra Reddy; Marian Lanyon; Andrew Markey; Gordon Plant; Michael Powell; Saurabh Sinha; John Wass
Journal:  Clin Endocrinol (Oxf)       Date:  2011-01       Impact factor: 3.478

  1 in total
  12 in total

Review 1.  Neuro-oncologic Emergencies.

Authors:  Paola Suarez-Meade; Lina Marenco-Hillembrand; Wendy J Sherman
Journal:  Curr Oncol Rep       Date:  2022-03-30       Impact factor: 5.945

2.  Delayed identification of massive pituitary apoplexy in pregnancy: A case report.

Authors:  Hari Sedai; Suraj Shrestha; Elisha Poddar; Pratima Sharma; Dipendra Dahal; Prajwal Khatiwada; Amit Pradhanang
Journal:  Int J Surg Case Rep       Date:  2022-09-27

Review 3.  HIV and the Pituitary Gland: Clinical and Biochemical Presentations.

Authors:  Joyce Youssef; Rohan Sadera; Dushyant Mital; Mohamed H Ahmed
Journal:  J Lab Physicians       Date:  2021-05-19

4.  The Effect of Timing of Surgery in Pituitary Apoplexy on Continuously Valued Visual Acuity.

Authors:  Patrick D Kelly; Shanik J Fernando; Jordan A Malenke; Rakesh K Chandra; Justin H Turner; Lola B Chambless
Journal:  J Neurol Surg B Skull Base       Date:  2020-01-24

5.  Clinical and biochemical characteristics of patients presenting with pituitary apoplexy.

Authors:  Ali Abbara; Sophie Clarke; Pei Chia Eng; James Milburn; Devavrata Joshi; Alexander N Comninos; Rozana Ramli; Amrish Mehta; Brynmor Jones; Florian Wernig; Ramesh Nair; Nigel Mendoza; Amir H Sam; Emma Hatfield; Karim Meeran; Waljit Singh Dhillo; Niamh M Martin
Journal:  Endocr Connect       Date:  2018-08-23       Impact factor: 3.335

Review 6.  Management of Hypopituitarism.

Authors:  Krystallenia I Alexandraki; AshleyB Grossman
Journal:  J Clin Med       Date:  2019-12-05       Impact factor: 4.241

7.  Pituitary haemorrhage and infarction: the spectrum of disease.

Authors:  Fizzah Iqbal; William Adams; Ioannis Dimitropoulos; Samiul Muquit; Daniel Flanagan
Journal:  Endocr Connect       Date:  2021-02       Impact factor: 3.335

8.  Acute elevation of interleukin 6 and matrix metalloproteinase 9 during the onset of pituitary apoplexy in Cushing's disease.

Authors:  Takako Araki; Jutarat Sangtian; Darin Ruanpeng; Ramachandra Tummala; Brent Clark; Lynn Burmeister; Daniel Peterson; Andrew S Venteicher; Yasuhiko Kawakami
Journal:  Pituitary       Date:  2021-05-26       Impact factor: 4.107

Review 9.  Landscape of Molecular Events in Pituitary Apoplexy.

Authors:  Prakamya Gupta; Pinaki Dutta
Journal:  Front Endocrinol (Lausanne)       Date:  2018-03-20       Impact factor: 5.555

10.  Society for Endocrinology endocrine emergency guidance.

Authors:  Marie Freel
Journal:  Endocr Connect       Date:  2016-09       Impact factor: 3.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.